Pulmonary arterial hypertension, a chronic lung disease, remains an unacceptable prognosis despite significant advances in conventional therapies. Stem cell therapy represents a novel and effective modality. This study was aimed to add new insight in gender differences of bone marrow-derived mesenchymal stem cells on therapy against pulmonary arterial hypertension and the underlying mechanism.
Introduction
Pulmonary arterial hypertension (PAH), a disorder that is closely associated with chronic inflammation and can be rapidly progressive and fatal, is characterized by elevated pulmonary artery pressure, arteriolar wall remodelling and right ventricular hypertrophy (RVH).
1,2 Despite significant advances in conventional therapies for PAH during the past decades, the prognosis remains very poor. Recent investigations have suggested that mesenchymal stem cells (MSCs) therapy represents a novel and effective modality. 3, 4 Interestingly, the potential importance of gender difference of stem cells on therapeutic efficiency were emphasized in animal studies on several types of diseases including fat tissue engineering, 4 ischaemia/reperfusion injury, 5 and articular cartilage defect model. 6 Ogawa et al. 4 showed that adipose-derived stromal cells (ASCs) harvested from female mice differentiated more efficiently into adipocytes than those from male mice, indicating a greater value of female ASCs on fat augmentation surgery such as breast reconstruction. In a study on ischaemia/reperfusion injury, female MSC-treated rat hearts demonstrated significantly a greater recovery of left ventricular function than male MSC-treated ones at the end of reperfusion. 5 Contrarily, there was also an important study showing better therapeutic potential of male stem cells than female † R.T. and J.L. are equally contributors to this work.
counterparts in an articular cartilage defect model. 6 The discrepancy suggests a possibility that the stem cell sex difference on therapeutic efficiency can be disease or tissue specific. Additionally, the underlying mechanism for gender differences of MSCs is likely multi-factorial. Some studies implied a major role of sex steroid hormones. 4, 5 Others indicated that female MSCs produced more growth factor and less inflammatory tumour necrosis factor alpha under stress. 7, 8 However, the mechanism underlying the distinct behaviour of female and male stem cells, particularly the intrinsic difference between female and male stem cells, remains largely unknown. Furthermore, to the best of our knowledge, there is no any report about gender difference of MSCs on therapy against PAH.
Methods
For details regarding methods, refer to the Supplementary material online, Methods.
Ethics statement and the animals used
C57BL/6J mice were used for stem cell isolation and transplantation as well as PAH models. All animal experiments were approved by the Institutional Animal Care and Use Committee.
Primary culture of MSCs
Bone marrow-derived mesenchymal stem cells (BMSCs) were obtained by flushing the femur and tibia diaphysis, cultured, and identified using Fluorescence Activated Cell Sorting (FACS).
In vivo experimental protocol
Female and male C57BL/6J mice, 20 -25 g, 8 -10 week old, received monocrotaline (MCT, 60 mg/kg) via tail vein to produce the PAH model.
9,10
BMSCs therapy protocol and experimental groups are available in Supplementary material online. Thirty days later, Fulton's index, the ratio of right ventricle weight over the weight of the left ventricle plus the septum RV/ (LV+S) was measured and lungs were harvested for the assessment of pulmonary artery muscularization. 
Measurement of [

Cell proliferation and migration assay
Cell proliferation was measured by an MTS colorimetric assay according to manufacturer's instructions (Cell Titer, Promega). BMSC migration assays were performed using 8-mm pore size chemotaxis filters within Boyden chamber inserts (Costar).
Western blot assay
GAPDH levels were analysed by western blot using specific antibody (Cell Signaling Technologies) according to the manufacturer's instructions. b-Actin and a-tubulin together served as a control for equal protein loading.
Plasmids and stable transfection
BMSCs in exponential growth were concurrently transfected with 2 mg of a siRNA vector (pGCsilencerTM U6/Neo/green fluorescent protein (GFP)/ RNAi vector, Genechem) or GAPDH-specific siRNA (pGCsilencerTM U6/ Neo/GFP/RNAi-GAPDH, Genechem) for female groups, or with an overexpression vector (pIRES2-ZsGreen1 vector, BioWit Technologies) or GAPDH-over-expressing plasmid (pIRES2-ZsGreen1-GAPDH, BioWit Technologies) for male groups.
MSC differentiation and immunohistochemistry in vivo
To detect localization and differentiation of transplanted GFP-expressing BMSCs into endothelial cells, immunohistochemistry for the lung tissues from receivers was performed using antibodies against GFP (Invitrogen) and von Willebrand Factor (vWF) (Santa Cruz Biotechnology).
2. 
Statistical analysis
Data are reported as means + SD of at least three independent experiments. SNK-q test and one-way analysis of variance analysis were used for two or multiple group comparisons. P , 0.05 was accepted as indicating statistical significance.
Results
Characterization of BMSCs
Mononuclear cells from male and female C57BL/6J mice of the same litter bone marrow were successfully isolated, expanded, and characterized. The cells were homogeneously long rhombus, fibroblast-like (Supplementary material online, Figure S1A ). We further identified BMSCs by FACS analysis. Over 99% cells expressed a typical MSC marker CD29, 15, 16 while rarely expressed haematopoietic markers CD45
(1.97 + 0.38%) and CD34 (0.34 + 0.13%) (Supplementary material online, Figure S1B -F).
Gender differences of BMSCs on therapeutic efficiency for MCT-induced PAH
Both the female and male mice treated with 3 weeks of MCT injection fully developed PAH 9,10 as illustrated by its resultant changes including elevations in RV/(LV+S) (P , 0.05, Figure 1A and B) and muscularization of pulmonary vessels (P , 0.05, Figure 1C -F). Then PAH mice were untreated, treated with female, or male BMSCs. Regardless of gender of the receiver, female and male BMSCs both significantly decreased Fulton's index RV/(LV+S) ( Figure 1A and B), an index of RVH. 17 Moreover, female BMSCs conferred markedly greater improvement of RV/ (LV+S) (P , 0.05). We also measured degree of muscularization in pulmonary resistance vessels (25-100 mm in diameter) to evaluate pulmonary vascular remodelling. Similarly, though male BMSCs treatment decreased degree of muscularization in both genders of MCT-injected mice (P , 0.05), female BMSCs always showed a significantly better therapeutic efficacy (P , 0.05, Figure 1C -F). Taken together, the above results indicated that both male and female BMSCs were effective against MCT-induced PAH in both genders of the mice, and female BMSCs possessed a better therapeutic efficiency than male cells either in a sex-matched or in a mismatched way. Figure 2F) . The cell migration assay showed that female BMSCs had a much higher basal migration capacity (P , 0.05). More importantly, histamine and H 2 O 2 treatment significantly enhanced the migration of female, not male BMSCs (P , 0.05, Figure 2G) .
Gender differences in [Ca
Collectively, the priority of female BMSCs in [Ca 2+ ] i kinetics and cellular behaviours may dependent on an intrinsic mechanism(s) between female and male BSMCs. 
GAPDH is critical in gender differences of BMSCs on [Ca 21 ] i kinetics and cellular behaviours
By accident, we found a higher expression level of GAPDH protein in female vs. male BSMCs (P , 0.05, Figure 3A and C and Supplementary material online, Figure S3 ). Noteworthy, both histamine and H 2 O 2 stimulation distinctly increased GAPDH expression in female BMSCs (P , 0.05), not in male BMSCs ( Figure 3A and C ) . These results indicated that histamine and H 2 O 2 treatment magnified the innate difference of the GAPDH protein level between female and male BMSCs.
To elucidate whether GAPDH is responsible for gender differences of BMSCs on [Ca 2+ ] i kinetics, we constructed GAPDH-over-expressing plasmid (OE-GAPDH) as well as specific siRNA against GAPDH and confirmed their efficiency by the western blot assay ( Figure 3B and D) . Figure 4A , the growth curves of female and male BMSCs apparently changed after GAPDH knockdown or over-expression, respectively. The growth speed comparison indicated that up-regulation of GAPDH protein promoted proliferation in male BMSCs, whereas down-regulation of GAPDH inhibited female BMSCs proliferation. By histamine and H 2 O 2 treatment, siRNA knockdown of GAPDH in female BMSCs abolished its priority on cell proliferation and migration in response to the stimuli. Meanwhile, over-expression of GAPDH protein in male BMSCs promoted their proliferation and migration property after histamine and H 2 O 2 stimulation (Figure 4B-E On the basis of above in vitro findings in the current study, we examined whether the gender differences between female and male BMSCs on therapeutic efficiency against MCT-induced PAH was affected by the GAPDH protein expression level. As shown in Figure 5A -D, siRNA knockdown of GAPDH resulted in the functional loss of female BMSCs on their superior improvement of RV/(LV+S) and pulmonary arterial muscularization (P , 0.05), whereas male BMSCs over-expressing GAPDH gained greater therapeutic efficiency against PAH by decreasing RV/(LV+S) and degree of arterial muscularization (P , 0.05). Furthermore, by immunohistochemistry, exogenous GFP-expressing BMSCs were found to have migrated to pulmonary blood vessels and differentiated into endothelial cells ( Figure 5E ), with these abilities greatly influenced by GAPDH ( Figure 5F and G). or b-Lapachone (bL) to inhibit or activate NAD(P)H:quinone oxidoreductase (NQO1). 24, 25 The results indicated that the NAD + /NADH ratio was higher in female BMSCs than in male cells ( Figure 6A) , consistent with the GAPDH expression level as showed in above data. Reversing NAD + /NADH ratio in female or male BMSCs by DIC or bL, [Ca 2+ ] i signalling, cell proliferation, and migration after histamine or H 2 O 2 became at least partially reversed ( Figure 6B ).
Discussion
Gender differences on stem cell therapy have been documented recently. Consistent with the previous studies on fat tissue augmentation and ischaemia/reperfusion injury, 4, 5 female BMSCs conferred greater protection against MCT-induced PAH than male BMSCs. Oppositely, in an articular cartilage defect rat model, 6 male BMSCs showed a better therapeutic potential than female counterparts. These findings emphasized the importance about gender differences of stem cells and the source gender a significant determinant for therapeutic efficiency. They also indicate that gender differences of stem cells are tissue or disease specific. Therefore, the examination of gender difference of stem cell therapy for different diseases like PAH in the current study becomes necessary and the understanding of underlying mechanisms would enable us to have better therapeutic strategies. Several recent reports have indicated that sex hormones influence the cellular activities of stem cells. 5, 26 In the current study, the comparison of sex-match and mismatch transplantations revealed that the sex of host tissue did not affect therapeutic efficiency of either female or male BMSCs (Figure 1) . Our result is consistent with a previous study 27 showing that female muscle-derived stem cells (MDSCs) had higher muscle regeneration efficiency, but failed to observe increased regeneration by normal male MDSCs transplanted into female mice or male MDSCs pre-stimulated with physiological oestrogen levels. These findings together with the results of other studies 28, 29 indicate that sexrelated differences might not be exclusively hormonal. Actually, some intracellular signalling pathways and the involved cellular responses to stress 27 were suggested for the explanation about stem cell gender differences. However, the underlying mechanism about the intrinsic difference of stem cell gender remains largely unknown. The major unexpected finding from the current study was that female BMSCs showed a much higher GAPDH protein level than male BMSCs. Noteworthy, by down-regulating GAPDH in female BMSCs or overexpressing this protein in male cells, the gender differences on inflammatory mediator-and oxidant stress-induced [ Increasing evidence demonstrates that mammalian GAPDH is not merely a simple 'housekeeping' protein, but a multifunctional protein with diverse activities instead. 30, 31 GAPDH was involved in the development of various diseases such as Parkinson's disease, 32 Alzheimer's disease, 33 and hepatocellular carcinoma. 34 In the present study, the GAPDH level was positively related to cell growth speed and the up-regulation of GAPDH promoted cell proliferation. The results are consistent with a novel finding that GAPDH was implicated in linking glucose availability to the growth and proliferation-promoting mTOR complex. 35 Moreover, our data indicate that GAPDH contributes to cell migration, although little is known about the associated mechanism. Patterson et al. 22 showed that GAPDH physiologically binds to the IP Some limitations of this study should be noted. First, the direct link between [Ca 2+ ] i signal kinetics and cellular behaviours needs to be verified in future investigation. Second, former investigations have defined the variability of GAPDH expression between tissues or alterations under pathological conditions like hypoxia. 18 Our results can only highlight the importance of GAPDH on gender differences of BMSCs in basal condition and a pathological circumstance of PAH. Further investigations about GAPDH in pulmonary tissues and particularly in the pathogenesis of PAH become warranted. It has been controversial in the literature about if MCT induced pulmonary hypertension in mice especially in earlier studies. 41 Our results are consistent with the more recent reports showing that MCT induced significant pulmonary hypertension in this type of animals. 9, 10 The reason for the discrepancy remains unclear; however, may be related with the dosage and or the application method of MCT in mice.
